柔软体作为一个有前途的纳米平台来增强托尔纳酸的眼部输送:配方,体外表征,统计优化,体外和微生物体外研究
Diana Aziz1, Sally Mohamed2, Saadia Tayel1
1Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
International journal of pharmaceutics
|October 4, 2023
概括
柔性体是一种新型纳米载体,可显著增强眼部药物输送. 这项研究表明,柔软体可以改善Tolnaftate.
科学领域:
- 眼科药物输送是眼科药物输送.
- 纳米技术纳米技术
- 药品制造 药品制造 药品制造
背景情况:
- 眼睛独特的生理学给药物输送带来了挑战.
- 新型纳米系统为增强眼部药物透和保留提供了潜力.
- 柔性体是眼科应用的有前途的纳米载体系统.
研究的目的:
- 评估柔软体作为Tolnaftate (TOL) 的眼部输送系统.
- 为了增强Tolnaftate的角膜透和抗真菌活性.
- 为了优化使用全因数设计的柔性体配方.
主要方法:
- 使用乙醇注射方法制备柔性体.
- 使用 3^1.2^2 完全因数设计的优化,变量为:氨基胺,水化量和边缘激活器.
- 用封装效率,粒子大小和泽塔潜力来表征柔软体.
- 外体和体内研究,以评估角膜透,安全性和抗真菌活性.
主要成果:
- 最佳的柔体配方 (FX5) 实现了高封装效率 (66.08%) 和合适的粒子大小 (154.99 nm).
- 与悬浮相比,FX5显著增加了Tolnaftate在角膜上的流量.
- 安全性评估 (德赖兹试验,组织病理学) 证实了FX5的眼睛耐受性.
- 在体内研究表明,FX5对Aspergillus niger的抗真菌活性优越且更持久.
结论:
- 柔性体是一种安全有效的纳米载体,用于眼部托尔纳夫酸的输送.
- 这种配方增强角膜透,并提供持续的抗真菌活性.
- 柔体是改善眼科药物疗效的有希望的方法.
相关概念视频
Factors Affecting Dissolution: Particle Size and Effective Surface Area
869
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
869
Drug Delivery: Overview
306
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
306


